Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mepolizumab
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
If approval is obtained, it would make Nucala the first targeted biologic treatment for patients with this rare and life-threatening disease caused by eosinophilic inflammation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nomacopan
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2020
Details:
All patients treated with nomacopan achieved the primary endpoint of transfusion independence.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ferric Maltol
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Beijing Aosaikang Pharmaceutical
Deal Size: $62.8 million Upfront Cash: $11.4 million
Deal Type: Licensing Agreement January 08, 2020
Details:
Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
